RNAi therapy hits cholesterol endpoints in two more Phase IIIs ahead of Medicines Co.'s submission

With readouts now in from three pivotal trials, Medicines Co. could seek a claim of reduced CV risk in its planned regulatory submissions of inclisiran for LDL-C reduction.

The announcement of results from the latest two trials drove shares of The

Read the full 408 word article

User Sign In